Inovio Pharmaceuticals, Inc. (INO)
USD 1.54
(-3.46%)
USD 1.54
(-3.46%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 55.59 Million USD | -55.94% |
| 2022 | 126.17 Million USD | 31.06% |
| 2021 | 96.27 Million USD | 22.43% |
| 2020 | 78.63 Million USD | -43.25% |
| 2019 | 138.54 Million USD | 214.3% |
| 2018 | 44.08 Million USD | -1.5% |
| 2017 | 44.75 Million USD | -11.08% |
| 2016 | 50.32 Million USD | 32.77% |
| 2015 | 37.9 Million USD | 87.22% |
| 2014 | 20.24 Million USD | -42.78% |
| 2013 | 35.38 Million USD | 244.16% |
| 2012 | 10.28 Million USD | -22.38% |
| 2011 | 13.24 Million USD | 47.72% |
| 2010 | 8.96 Million USD | -53.89% |
| 2009 | 19.44 Million USD | -2.2% |
| 2008 | 19.88 Million USD | 127.46% |
| 2007 | 8.74 Million USD | -1.87% |
| 2006 | 8.9 Million USD | 61.71% |
| 2005 | 5.5 Million USD | 1.97% |
| 2004 | 5.4 Million USD | 357.27% |
| 2003 | 1.18 Million USD | -30.26% |
| 2002 | 1.69 Million USD | 1.39% |
| 2001 | 1.67 Million USD | -23.41% |
| 2000 | 2.18 Million USD | 45.41% |
| 1999 | 1.5 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 34.67 Million USD | -37.63% |
| 2024 Q2 | 37.05 Million USD | 6.88% |
| 2023 Q4 | 55.59 Million USD | 1.2% |
| 2023 Q2 | 63.66 Million USD | -5.5% |
| 2023 Q3 | 54.93 Million USD | -13.71% |
| 2023 FY | 55.59 Million USD | -55.94% |
| 2023 Q1 | 67.36 Million USD | -46.6% |
| 2022 FY | 126.17 Million USD | 31.06% |
| 2022 Q4 | 126.17 Million USD | 0.72% |
| 2022 Q1 | 90.42 Million USD | -6.07% |
| 2022 Q2 | 161.72 Million USD | 78.85% |
| 2022 Q3 | 125.27 Million USD | -22.54% |
| 2021 FY | 96.27 Million USD | 22.43% |
| 2021 Q3 | 82.19 Million USD | -1.32% |
| 2021 Q2 | 83.28 Million USD | 13.69% |
| 2021 Q1 | 73.25 Million USD | -6.84% |
| 2021 Q4 | 96.27 Million USD | 17.13% |
| 2020 Q4 | 78.63 Million USD | -30.91% |
| 2020 FY | 78.63 Million USD | -43.25% |
| 2020 Q3 | 113.81 Million USD | -55.68% |
| 2020 Q2 | 256.82 Million USD | 70.01% |
| 2020 Q1 | 151.06 Million USD | 9.04% |
| 2019 Q4 | 138.54 Million USD | 20.04% |
| 2019 Q3 | 115.41 Million USD | 6.28% |
| 2019 FY | 138.54 Million USD | 214.3% |
| 2019 Q2 | 108.59 Million USD | -1.46% |
| 2019 Q1 | 110.19 Million USD | 149.99% |
| 2018 Q1 | 60.57 Million USD | 35.35% |
| 2018 FY | 44.08 Million USD | -1.5% |
| 2018 Q4 | 44.08 Million USD | 19.18% |
| 2018 Q3 | 36.98 Million USD | -1.19% |
| 2018 Q2 | 37.43 Million USD | -38.2% |
| 2017 Q1 | 47.36 Million USD | -5.88% |
| 2017 FY | 44.75 Million USD | -11.08% |
| 2017 Q4 | 44.75 Million USD | 7.67% |
| 2017 Q3 | 41.56 Million USD | 17.66% |
| 2017 Q2 | 35.32 Million USD | -25.43% |
| 2016 Q2 | 41.89 Million USD | 4.55% |
| 2016 FY | 50.32 Million USD | 32.77% |
| 2016 Q3 | 47.57 Million USD | 13.55% |
| 2016 Q4 | 50.32 Million USD | 5.8% |
| 2016 Q1 | 40.07 Million USD | 5.71% |
| 2015 Q1 | 14.42 Million USD | -28.74% |
| 2015 FY | 37.9 Million USD | 87.22% |
| 2015 Q3 | 37.38 Million USD | 80.21% |
| 2015 Q2 | 20.74 Million USD | 43.77% |
| 2015 Q4 | 37.9 Million USD | 1.4% |
| 2014 Q3 | 17.48 Million USD | -12.05% |
| 2014 Q2 | 19.88 Million USD | -11.54% |
| 2014 FY | 20.24 Million USD | -42.78% |
| 2014 Q1 | 22.47 Million USD | -36.48% |
| 2014 Q4 | 20.24 Million USD | 15.78% |
| 2013 Q3 | 25.79 Million USD | 21.0% |
| 2013 Q2 | 21.32 Million USD | 19.91% |
| 2013 FY | 35.38 Million USD | 244.16% |
| 2013 Q1 | 17.78 Million USD | 72.94% |
| 2013 Q4 | 35.38 Million USD | 37.15% |
| 2012 Q2 | 12.23 Million USD | -19.08% |
| 2012 Q4 | 10.28 Million USD | -22.09% |
| 2012 FY | 10.28 Million USD | -22.38% |
| 2012 Q1 | 15.12 Million USD | 14.17% |
| 2012 Q3 | 13.19 Million USD | 7.84% |
| 2011 FY | 13.24 Million USD | 47.72% |
| 2011 Q3 | 11.96 Million USD | -2.56% |
| 2011 Q1 | 16.6 Million USD | 85.15% |
| 2011 Q4 | 13.24 Million USD | 10.72% |
| 2011 Q2 | 12.27 Million USD | -26.05% |
| 2010 FY | 8.96 Million USD | -53.89% |
| 2010 Q4 | 8.96 Million USD | 15.18% |
| 2010 Q1 | 20.4 Million USD | 4.93% |
| 2010 Q3 | 7.78 Million USD | -6.49% |
| 2010 Q2 | 8.32 Million USD | -59.2% |
| 2009 Q4 | 19.44 Million USD | -12.62% |
| 2009 Q1 | 20.16 Million USD | 1.43% |
| 2009 FY | 19.44 Million USD | -2.2% |
| 2009 Q2 | 25.41 Million USD | 26.04% |
| 2009 Q3 | 22.25 Million USD | -12.44% |
| 2008 Q3 | 9.47 Million USD | 8.99% |
| 2008 FY | 19.88 Million USD | 127.46% |
| 2008 Q4 | 19.88 Million USD | 109.72% |
| 2008 Q1 | 8.11 Million USD | -7.12% |
| 2008 Q2 | 8.69 Million USD | 7.14% |
| 2007 Q3 | 8.33 Million USD | -0.01% |
| 2007 FY | 8.74 Million USD | -1.87% |
| 2007 Q1 | 8.17 Million USD | -8.26% |
| 2007 Q2 | 8.33 Million USD | 2.0% |
| 2007 Q4 | 8.74 Million USD | 4.88% |
| 2006 Q2 | 4.16 Million USD | -8.77% |
| 2006 Q1 | 4.56 Million USD | -17.11% |
| 2006 FY | 8.9 Million USD | 61.71% |
| 2006 Q4 | 8.9 Million USD | 122.15% |
| 2006 Q3 | 4 Million USD | -3.74% |
| 2005 Q4 | 5.5 Million USD | 35.64% |
| 2005 FY | 5.5 Million USD | 1.97% |
| 2005 Q3 | 4.06 Million USD | -21.55% |
| 2005 Q2 | 5.17 Million USD | -8.43% |
| 2005 Q1 | 5.65 Million USD | 4.65% |
| 2004 Q3 | 3.27 Million USD | 78.01% |
| 2004 Q4 | 5.4 Million USD | 64.81% |
| 2004 Q2 | 1.84 Million USD | 119.15% |
| 2004 FY | 5.4 Million USD | 357.27% |
| 2004 Q1 | 840.16 Thousand USD | -28.88% |
| 2003 Q4 | 1.18 Million USD | 14.09% |
| 2003 FY | 1.18 Million USD | -30.26% |
| 2003 Q1 | 916.75 Thousand USD | -45.88% |
| 2003 Q2 | 785.96 Thousand USD | -14.27% |
| 2003 Q3 | 1.03 Million USD | 31.75% |
| 2002 FY | 1.69 Million USD | 1.39% |
| 2002 Q1 | 1.37 Million USD | -17.88% |
| 2002 Q2 | 1.22 Million USD | -10.36% |
| 2002 Q3 | 1.28 Million USD | 4.5% |
| 2002 Q4 | 1.69 Million USD | 31.79% |
| 2001 FY | 1.67 Million USD | -23.41% |
| 2001 Q1 | 1.59 Million USD | -2.17% |
| 2001 Q2 | 1.58 Million USD | -0.8% |
| 2001 Q4 | 1.67 Million USD | 14.8% |
| 2001 Q3 | 1.45 Million USD | -8.09% |
| 2000 Q3 | 1.64 Million USD | -18.76% |
| 2000 FY | 2.18 Million USD | 45.41% |
| 2000 Q1 | 2.18 Million USD | 3.86% |
| 2000 Q2 | 2.02 Million USD | -7.14% |
| 2000 Q4 | 1.63 Million USD | -0.84% |
| 1999 Q2 | 1.4 Million USD | -6.67% |
| 1999 FY | 1.5 Million USD | 0.0% |
| 1999 Q1 | 1.5 Million USD | 15.38% |
| 1999 Q3 | 1.8 Million USD | 28.57% |
| 1999 Q4 | 2.1 Million USD | 16.67% |
| 1998 Q4 | 1.3 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AbCellera Biologics Inc. | 335.77 Million USD | 83.443% |
| Alkermes plc | 933.53 Million USD | 94.045% |
| Agenus Inc. | 462.29 Million USD | 87.974% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | 98.627% |
| Aptorum Group Limited | 5.25 Million USD | -957.601% |
| Ardelyx, Inc. | 130.76 Million USD | 57.484% |
| Arrowhead Pharmaceuticals, Inc. | 478.39 Million USD | 88.379% |
| Bicycle Therapeutics plc | 224.41 Million USD | 75.226% |
| BioXcel Therapeutics, Inc. | 130.21 Million USD | 57.303% |
| ChromaDex Corporation | 26.5 Million USD | -109.73% |
| Chimerix, Inc. | 19.74 Million USD | -181.566% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -58.044% |
| Caribou Biosciences, Inc. | 72.56 Million USD | 23.388% |
| CRISPR Therapeutics AG | 346.76 Million USD | 83.968% |
| Precision BioSciences, Inc. | 140.92 Million USD | 60.548% |
| Dyadic International, Inc. | 2.34 Million USD | -2275.206% |
| Eton Pharmaceuticals, Inc. | 16.26 Million USD | -241.851% |
| Fortress Biotech, Inc. | 165.93 Million USD | 66.497% |
| Lantern Pharma Inc. | 2.73 Million USD | -1929.261% |
| HOOKIPA Pharma Inc. | 71.48 Million USD | 22.223% |
| Inhibikase Therapeutics, Inc. | 3.52 Million USD | -1475.507% |
| Incyte Corporation | 1.59 Billion USD | 96.508% |
| IO Biotech, Inc. | 17.55 Million USD | -216.674% |
| Jaguar Health, Inc. | 45.86 Million USD | -21.212% |
| Novavax, Inc. | 2.57 Billion USD | 97.839% |
| Janux Therapeutics, Inc. | 36.05 Million USD | -54.183% |
| Opthea Limited | 264.6 Million USD | 78.989% |
| Ligand Pharmaceuticals Incorporated | 130.7 Million USD | 57.466% |
| ContextLogic Inc. | 206 Million USD | 73.012% |
| MiMedx Group, Inc. | 96.33 Million USD | 42.287% |
| Pyxis Oncology, Inc. | 48.02 Million USD | -15.77% |
| TransCode Therapeutics, Inc. | 3.52 Million USD | -1475.434% |
| NextCure, Inc. | 14.99 Million USD | -270.709% |
| Ocuphire Pharma, Inc. | 4.04 Million USD | -1275.44% |
| Oncternal Therapeutics, Inc. | 6.67 Million USD | -732.639% |
| Outlook Therapeutics, Inc. | 46.73 Million USD | -18.948% |
| Vaxcyte, Inc. | 167.44 Million USD | 66.799% |
| PDS Biotechnology Corporation | 33.25 Million USD | -67.158% |
| Madrigal Pharmaceuticals, Inc. | 235.21 Million USD | 76.364% |
| Pharming Group N.V. | 244.07 Million USD | 77.222% |
| Pieris Pharmaceuticals, Inc. | 11.92 Million USD | -366.325% |
| Avidity Biosciences, Inc. | 127.79 Million USD | 56.495% |
| Reviva Pharmaceuticals Holdings, Inc. | 6.6 Million USD | -741.425% |
| Reviva Pharmaceuticals Holdings, Inc. | 6.6 Million USD | -741.425% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | 32.557% |
| Sol-Gel Technologies Ltd. | 6.64 Million USD | -736.9% |
| Acelyrin, Inc. | 86.35 Million USD | 35.619% |
| Salarius Pharmaceuticals, Inc. | 1.29 Million USD | -4179.059% |
| SELLAS Life Sciences Group, Inc. | 14.37 Million USD | -286.642% |
| Summit Therapeutics Inc. | 125.25 Million USD | 55.615% |
| Sensei Biotherapeutics, Inc. | 9.47 Million USD | -486.51% |
| Senti Biosciences, Inc. | 52.57 Million USD | -5.753% |
| Stoke Therapeutics, Inc. | 68.77 Million USD | 19.166% |
| Syros Pharmaceuticals, Inc. | 151.51 Million USD | 63.306% |
| Alaunos Therapeutics, Inc. | 1.95 Million USD | -2742.295% |
| Telomir Pharmaceuticals, Inc. Common Stock | 1.33 Million USD | -4062.683% |
| Entrada Therapeutics, Inc. | 226.83 Million USD | 75.491% |
| VistaGen Therapeutics, Inc. | 9.36 Million USD | -493.523% |
| Wave Life Sciences Ltd. | 227.44 Million USD | 75.557% |
| Sorrento Therapeutics, Inc. | 494.5 Million USD | 88.757% |
| TRACON Pharmaceuticals, Inc. | 10.91 Million USD | -409.394% |
| Barinthus Biotherapeutics plc | 27.51 Million USD | -102.084% |
| Psyence Biomedical Ltd. | 12.1 Million USD | -359.287% |
| Phathom Pharmaceuticals, Inc. | 486.6 Million USD | 88.575% |
| Immix Biopharma, Inc. | 3.72 Million USD | -1393.781% |
| Keros Therapeutics, Inc. | 37.81 Million USD | -47.031% |
| MEI Pharma, Inc. | 8.35 Million USD | -565.413% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | -91.609% |
| Xeris Biopharma Holdings, Inc. | 347.58 Million USD | 84.005% |
| Rigel Pharmaceuticals, Inc. | 145.86 Million USD | 61.887% |
| Fortress Biotech, Inc. | 165.93 Million USD | 66.497% |
| Precigen, Inc. | 41.64 Million USD | -33.501% |
| Clearside Biomedical, Inc. | 49.93 Million USD | -11.346% |
| AlloVir, Inc. | 45.01 Million USD | -23.504% |
| C4 Therapeutics, Inc. | 130.33 Million USD | 57.345% |
| Fate Therapeutics, Inc. | 137.8 Million USD | 59.655% |
| ImmuCell Corporation | 18.81 Million USD | -195.483% |
| IDEAYA Biosciences, Inc. | 28.22 Million USD | -96.965% |
| Onconetix, Inc. | 23.18 Million USD | -139.832% |
| PureTech Health plc | 125.58 Million USD | 55.73% |
| VYNE Therapeutics Inc. | 8.95 Million USD | -521.176% |
| Elevation Oncology, Inc. | 34.28 Million USD | -62.171% |
| Kintara Therapeutics, Inc. | 2.44 Million USD | -2173.836% |
| Seer, Inc. | 39.36 Million USD | -41.23% |
| Verrica Pharmaceuticals Inc. | 61.83 Million USD | 10.089% |
| Innoviva, Inc. | 568.55 Million USD | 90.222% |
| Aadi Bioscience, Inc. | 27.22 Million USD | -104.184% |
| ESSA Pharma Inc. | 3.49 Million USD | -1490.677% |
| GlycoMimetics, Inc. | 6.9 Million USD | -705.487% |
| GT Biopharma, Inc. | 6.63 Million USD | -738.162% |
| Inhibrx Biosciences, Inc. | 264.39 Million USD | 78.972% |
| Akebia Therapeutics, Inc. | 272.28 Million USD | 79.582% |
| Catalyst Pharmaceuticals, Inc. | 84.02 Million USD | 33.836% |
| Longboard Pharmaceuticals, Inc. | 9.77 Million USD | -468.808% |
| Orchestra BioMed Holdings, Inc. | 27.16 Million USD | -104.628% |
| Alzamend Neuro, Inc. | 3.22 Million USD | -1623.472% |
| Rocket Pharmaceuticals, Inc. | 73.76 Million USD | 24.634% |
| Aptose Biosciences Inc. | 15.8 Million USD | -251.675% |
| ZyVersa Therapeutics, Inc. | 11.03 Million USD | -403.595% |
| Soligenix, Inc. | 7.27 Million USD | -664.207% |
| Century Therapeutics, Inc. | 175.94 Million USD | 68.401% |
| Kura Oncology, Inc. | 51.66 Million USD | -7.614% |
| TScan Therapeutics, Inc. | 121.28 Million USD | 54.16% |
| Intensity Therapeutics, Inc. | 4.13 Million USD | -1245.156% |
| Ocean Biomedical, Inc. | 6.61 Million USD | -740.588% |
| CytomX Therapeutics, Inc. | 252.59 Million USD | 77.991% |
| Autolus Therapeutics plc | 263.9 Million USD | 78.934% |
| Mineralys Therapeutics, Inc. | 10.48 Million USD | -430.388% |
| EyePoint Pharmaceuticals, Inc. | 88.86 Million USD | 37.436% |
| Eterna Therapeutics Inc. | 46.89 Million USD | -18.543% |
| Adaptive Biotechnologies Corporation | 352.85 Million USD | 84.244% |
| GRI Bio, Inc. | 2.69 Million USD | -1961.375% |
| Xenetic Biosciences, Inc. | 809.58 Thousand USD | -6767.135% |
| Tenaya Therapeutics, Inc. | 31.09 Million USD | -78.815% |
| IGM Biosciences, Inc. | 220.17 Million USD | 74.75% |
| INmune Bio, Inc. | 18.86 Million USD | -194.748% |
| Heron Therapeutics, Inc. | 256.47 Million USD | 78.324% |
| SAB Biotherapeutics, Inc. | 26.64 Million USD | -108.677% |
| Pasithea Therapeutics Corp. | 2.71 Million USD | -1945.143% |
| Entero Therapeutics, Inc. | 3.28 Million USD | -1594.841% |
| Milestone Pharmaceuticals Inc. | 58.45 Million USD | 4.892% |
| X4 Pharmaceuticals, Inc. | 96.15 Million USD | 42.184% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | 79.0% |
| Coherus BioSciences, Inc. | 823.02 Million USD | 93.245% |
| Verastem, Inc. | 71.18 Million USD | 21.9% |
| Abeona Therapeutics Inc. | 49.17 Million USD | -13.054% |
| Pliant Therapeutics, Inc. | 38.57 Million USD | -44.111% |
| Tonix Pharmaceuticals Holding Corp. | 48.93 Million USD | -13.617% |
| Histogen Inc. | 5.69 Million USD | -875.87% |
| Aprea Therapeutics, Inc. | 4.38 Million USD | -1167.677% |
| Surrozen, Inc. | 8.14 Million USD | -582.57% |
| Organovo Holdings, Inc. | 2.74 Million USD | -1923.118% |
| Lixte Biotechnology Holdings, Inc. | 313.85 Thousand USD | -17613.518% |
| Ovid Therapeutics Inc. | 56.22 Million USD | 1.129% |
| Panbela Therapeutics, Inc. | 16.51 Million USD | -236.696% |
| CASI Pharmaceuticals, Inc. | 51.1 Million USD | -8.791% |
| Cadrenal Therapeutics, Inc. Common Stock | 826.87 Thousand USD | -6623.543% |
| Centessa Pharmaceuticals plc | 126.72 Million USD | 56.129% |
| Hepion Pharmaceuticals, Inc. | 10.81 Million USD | -414.124% |
| Arcturus Therapeutics Holdings Inc. | 150.88 Million USD | 63.155% |
| BioRestorative Therapies, Inc. | 2.6 Million USD | -2032.257% |
| Apollomics, Inc. | 14.15 Million USD | -292.816% |
| Amarin Corporation plc | 279.58 Million USD | 80.115% |
| Mesoblast Limited | 188.79 Million USD | 70.553% |
| Turnstone Biologics Corp. | 14.14 Million USD | -292.955% |
| Kymera Therapeutics, Inc. | 180.78 Million USD | 69.248% |
| Synaptogenix, Inc. | 5.52 Million USD | -905.436% |
| Tiziana Life Sciences Ltd | 6.64 Million USD | -736.271% |
| Aurinia Pharmaceuticals Inc. | 170.1 Million USD | 67.318% |
| BriaCell Therapeutics Corp. | 8.55 Million USD | -549.691% |
| Monopar Therapeutics Inc. | 1.75 Million USD | -3063.509% |
| Exelixis, Inc. | 678.44 Million USD | 91.805% |
| Better Therapeutics, Inc. | 23.84 Million USD | -133.182% |
| Nurix Therapeutics, Inc. | 164.04 Million USD | 66.11% |
| Apellis Pharmaceuticals, Inc. | 594.2 Million USD | 90.644% |
| NLS Pharmaceutics AG | 10.68 Million USD | -420.545% |
| Dermata Therapeutics, Inc. | 1.62 Million USD | -3324.165% |
| Aridis Pharmaceuticals, Inc. | 38.92 Million USD | -42.819% |
| Gritstone bio, Inc. | 125.91 Million USD | 55.848% |
| Jasper Therapeutics, Inc. | 14.67 Million USD | -278.818% |
| TNF Pharmaceuticals, Inc. | 5.08 Million USD | -992.54% |
| Avid Bioservices, Inc. | 275.66 Million USD | 79.833% |
| Insmed Incorporated | 1.66 Billion USD | 96.654% |
| Virpax Pharmaceuticals, Inc. | 7.69 Million USD | -622.578% |
| MediWound Ltd. | 27.18 Million USD | -104.492% |
| OmniAb, Inc. | 87.4 Million USD | 36.39% |
| Alector, Inc. | 487.66 Million USD | 88.6% |
| Seres Therapeutics, Inc. | 403.45 Million USD | 86.22% |
| Checkpoint Therapeutics, Inc. | 18.42 Million USD | -201.738% |
| Viracta Therapeutics, Inc. | 38.37 Million USD | -44.881% |
| Zai Lab Limited | 240.17 Million USD | 76.852% |
| Revance Therapeutics, Inc. | 630.05 Million USD | 91.176% |
| Aura Biosciences, Inc. | 29.22 Million USD | -90.219% |
| Lyell Immunopharma, Inc. | 95.07 Million USD | 41.526% |
| Immunic, Inc. | 25.36 Million USD | -119.155% |
| Tarsus Pharmaceuticals, Inc. | 69.23 Million USD | 19.702% |
| Veracyte, Inc. | 93.71 Million USD | 40.679% |
| InMed Pharmaceuticals Inc. | 2.61 Million USD | -2024.656% |
| FibroGen, Inc. | 585.72 Million USD | 90.508% |
| SeaStar Medical Holding Corporation | 17.38 Million USD | -219.826% |
| Adial Pharmaceuticals, Inc. | 653.07 Thousand USD | -8412.837% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.65 Million USD | -883.038% |
| Jazz Pharmaceuticals plc | 7.65 Billion USD | 99.274% |
| Cyclacel Pharmaceuticals, Inc. | 8.19 Million USD | -578.157% |
| Amylyx Pharmaceuticals, Inc. | 84.02 Million USD | 33.832% |
| TG Therapeutics, Inc. | 169.08 Million USD | 67.12% |
| Galecto, Inc. | 5.89 Million USD | -842.932% |
| Calithera Biosciences, Inc. | 8.28 Million USD | -571.117% |
| Fortrea Holdings Inc. | 2.61 Billion USD | 97.877% |
| KalVista Pharmaceuticals, Inc. | 28.82 Million USD | -92.892% |
| Aptevo Therapeutics Inc. | 12.62 Million USD | -340.498% |
| XBiotech Inc. | 8.39 Million USD | -562.085% |
| Jasper Therapeutics, Inc. | 14.67 Million USD | -278.818% |
| Lyra Therapeutics, Inc. | 53.18 Million USD | -4.542% |
| Foghorn Therapeutics Inc. | 363.1 Million USD | 84.689% |
| Y-mAbs Therapeutics, Inc. | 26.88 Million USD | -106.797% |
| Theravance Biopharma, Inc. | 169 Million USD | 67.104% |
| Ultragenyx Pharmaceutical Inc. | 1.21 Billion USD | 95.427% |
| Metagenomi, Inc. Common Stock | 500.42 Million USD | 88.89% |
| Vaxxinity, Inc. | 30.94 Million USD | -79.664% |
| BioCryst Pharmaceuticals, Inc. | 972.48 Million USD | 94.283% |
| Gain Therapeutics, Inc. | 6.03 Million USD | -821.809% |
| Cartesian Therapeutics, Inc. | 745.23 Million USD | 92.54% |
| NexImmune, Inc. | 5.08 Million USD | -993.485% |
| Creative Medical Technology Holdings, Inc. | 371.39 Thousand USD | -14869.357% |
| Marker Therapeutics, Inc. | 3.07 Million USD | -1708.066% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 99.218% |
| Chemomab Therapeutics Ltd. | 5.15 Million USD | -978.676% |
| Scopus BioPharma Inc. | 7.45 Million USD | -645.802% |
| RAPT Therapeutics, Inc. | 26.29 Million USD | -111.437% |
| Ainos, Inc. | 7.39 Million USD | -651.875% |
| Pluri Inc. | 34.11 Million USD | -62.979% |
| Prothena Corporation plc | 135.01 Million USD | 58.823% |
| Adaptimmune Therapeutics plc | 243.1 Million USD | 77.131% |
| Celularity Inc. | 102.92 Million USD | 45.987% |
| Rallybio Corporation | 9.43 Million USD | -489.183% |
| Cue Biopharma, Inc. | 24.44 Million USD | -127.43% |
| MeiraGTx Holdings plc | 319.99 Million USD | 82.626% |
| Omeros Corporation | 403.25 Million USD | 86.213% |
| Humacyte, Inc. | 114.67 Million USD | 51.52% |
| Immunocore Holdings plc | 228.15 Million USD | 75.633% |
| Cocrystal Pharma, Inc. | 4.87 Million USD | -1040.416% |
| Cidara Therapeutics, Inc. | 76.74 Million USD | 27.554% |
| Blueprint Medicines Corporation | 918.64 Million USD | 93.948% |
| CalciMedica, Inc. | 4.02 Million USD | -1280.221% |
| Cabaletta Bio, Inc. | 17.45 Million USD | -218.561% |
| Marinus Pharmaceuticals, Inc. | 154.14 Million USD | 63.933% |
| Scholar Rock Holding Corporation | 85.81 Million USD | 35.216% |
| Sana Biotechnology, Inc. | 277.79 Million USD | 79.987% |
| Pulmatrix, Inc. | 15.96 Million USD | -248.276% |
| Elicio Therapeutics, Inc. | 15.77 Million USD | -252.471% |
| Vigil Neuroscience, Inc. | 24.6 Million USD | -125.942% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | 77.834% |
| Adlai Nortye Ltd. American Depositary Shares | 50.78 Million USD | -9.47% |
| Cytokinetics, Incorporated | 1.21 Billion USD | 95.408% |
| Eloxx Pharmaceuticals, Inc. | 31.78 Million USD | -74.921% |
| Nutriband Inc. | 1.07 Million USD | -5052.87% |
| Protara Therapeutics, Inc. | 10.63 Million USD | -422.856% |
| Vor Biopharma Inc. | 59.1 Million USD | 5.936% |
| Roivant Sciences Ltd. | 773.95 Million USD | 92.817% |
| Evogene Ltd. | 17.99 Million USD | -209.034% |
| ProKidney Corp. | 29.21 Million USD | -90.291% |
| Applied Therapeutics, Inc. | 71.97 Million USD | 22.762% |
| Hoth Therapeutics, Inc. | 704.98 Thousand USD | -7786.047% |
| BridgeBio Pharma, Inc. | 1.88 Billion USD | 97.057% |
| CorMedix Inc. | 11.91 Million USD | -366.5% |
| BioLineRx Ltd. | 50.7 Million USD | -9.651% |
| Tango Therapeutics, Inc. | 149.45 Million USD | 62.802% |
| Galectin Therapeutics Inc. | 88.44 Million USD | 37.139% |
| Atai Life Sciences N.V. | 49.16 Million USD | -13.086% |
| Renovaro Biosciences Inc. | 31.15 Million USD | -78.463% |
| Aerovate Therapeutics, Inc. | 17.96 Million USD | -209.516% |
| Zentalis Pharmaceuticals, Inc. | 124.63 Million USD | 55.394% |
| Sagimet Biosciences Inc. | 5.65 Million USD | -883.291% |
| MediciNova, Inc. | 3.89 Million USD | -1328.615% |
| Praxis Precision Medicines, Inc. | 18.27 Million USD | -204.148% |
| Cardio Diagnostics Holdings, Inc. | 1.5 Million USD | -3595.903% |
| GeoVax Labs, Inc. | 3.51 Million USD | -1479.465% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | 86.005% |
| Biomea Fusion, Inc. | 30.69 Million USD | -81.151% |
| PTC Therapeutics, Inc. | 2.72 Billion USD | 97.957% |
| Mereo BioPharma Group plc | 15.96 Million USD | -248.298% |
| Cullinan Oncology, Inc. | 31.2 Million USD | -78.184% |
| Syndax Pharmaceuticals, Inc. | 58.68 Million USD | 5.263% |
| Absci Corporation | 58.3 Million USD | 4.646% |
| NRx Pharmaceuticals, Inc. | 19.04 Million USD | -191.869% |
| 4D Molecular Therapeutics, Inc. | 32.06 Million USD | -73.399% |
| Dyne Therapeutics, Inc. | 73.79 Million USD | 24.657% |
| Kiniksa Pharmaceuticals, Ltd. | 87.48 Million USD | 36.45% |
| Ventyx Biosciences, Inc. | 33.77 Million USD | -64.629% |
| Allakos Inc. | 74.79 Million USD | 25.668% |
| Imunon, Inc. | 8.53 Million USD | -551.729% |
| Fulcrum Therapeutics, Inc. | 22.5 Million USD | -147.079% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | 51.577% |
| BioAtla, Inc. | 48.98 Million USD | -13.492% |
| NLS Pharmaceutics AG | 10.68 Million USD | -420.545% |
| Bio-Path Holdings, Inc. | 2.77 Million USD | -1900.55% |
| Allogene Therapeutics, Inc. | 130.6 Million USD | 57.432% |
| Larimar Therapeutics, Inc. | 14.21 Million USD | -291.103% |
| XOMA Corporation | 145.58 Million USD | 61.811% |
| Kezar Life Sciences, Inc. | 33.66 Million USD | -65.143% |
| Cara Therapeutics, Inc. | 68.75 Million USD | 19.145% |
| aTyr Pharma, Inc. | 31.59 Million USD | -75.951% |
| Aligos Therapeutics, Inc. | 61.82 Million USD | 10.073% |
| Akero Therapeutics, Inc. | 44.96 Million USD | -23.641% |
| Viridian Therapeutics, Inc. | 48.4 Million USD | -14.862% |
| Eliem Therapeutics, Inc. | 2.87 Million USD | -1837.118% |
| EyeGate Pharmaceuticals, Inc. | 8.15 Million USD | -581.48% |
| Akari Therapeutics, Plc | 4.58 Million USD | -1112.812% |
| Tevogen Bio Holdings Inc. | 17.73 Million USD | -213.511% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | 96.629% |
| Lexaria Bioscience Corp. | 403.9 Thousand USD | -13664.346% |
| UroGen Pharma Ltd. | 243.52 Million USD | 77.17% |
| Sutro Biopharma, Inc. | 321.08 Million USD | 82.685% |
| ZIVO Bioscience, Inc. | 2.76 Million USD | -1913.186% |
| Orgenesis Inc. | 35.53 Million USD | -56.452% |
| Entera Bio Ltd. | 1.37 Million USD | -3931.566% |
| GH Research PLC | 6.7 Million USD | -729.657% |
| Lisata Therapeutics, Inc. | 6.8 Million USD | -717.578% |
| Reneo Pharmaceuticals, Inc. | 18.82 Million USD | -195.311% |
| Xencor, Inc. | 283.55 Million USD | 80.394% |
| 60 Degrees Pharmaceuticals, Inc. | 2.98 Million USD | -1762.068% |
| Replimune Group, Inc. | 113.21 Million USD | 50.894% |
| Coeptis Therapeutics Holdings, Inc. | 3.75 Million USD | -1379.73% |
| Vanda Pharmaceuticals Inc. | 103.53 Million USD | 46.3% |
| Lexaria Bioscience Corp. | 403.9 Thousand USD | -13664.346% |
| Portage Biotech Inc. | 4.45 Million USD | -1149.332% |
| Cardio Diagnostics Holdings, Inc. | 1.5 Million USD | -3595.903% |
| Olema Pharmaceuticals, Inc. | 23.05 Million USD | -141.194% |
| OncoCyte Corporation | 49.29 Million USD | -12.774% |
| Qualigen Therapeutics, Inc. | 4.13 Million USD | -1243.919% |
| Processa Pharmaceuticals, Inc. | 797.48 Thousand USD | -6871.337% |
| Purple Biotech Ltd. | 10 Million USD | -455.675% |
| CollPlant Biotechnologies Ltd. | 5.78 Million USD | -860.859% |
| scPharmaceuticals Inc. | 57.26 Million USD | 2.909% |
| ProMIS Neurosciences, Inc. | 12.38 Million USD | -348.783% |
| HilleVax, Inc. | 78.9 Million USD | 29.545% |
| NeuroSense Therapeutics Ltd. | 5.05 Million USD | -1000.897% |
| Tharimmune, Inc. | 1.81 Million USD | -2963.024% |
| Genprex, Inc. | 3.25 Million USD | -1608.412% |
| Neumora Therapeutics, Inc. Common Stock | 27.11 Million USD | -105.005% |
| Atossa Therapeutics, Inc. | 5.23 Million USD | -961.789% |
| XTL Biopharmaceuticals Ltd. | 206 Thousand USD | -26888.007% |
| Virios Therapeutics, Inc. | 358.54 Thousand USD | -15405.677% |
| OKYO Pharma Limited | 7.42 Million USD | -649.177% |
| Savara Inc. | 37.19 Million USD | -49.482% |
| Curis, Inc. | 57.61 Million USD | 3.5% |
| Daré Bioscience, Inc. | 26.32 Million USD | -111.149% |
| Carmell Therapeutics Corporation | 39.19 Million USD | -41.825% |
| Titan Pharmaceuticals, Inc. | 1.44 Million USD | -3750.09% |
| Achieve Life Sciences, Inc. | 20.81 Million USD | -167.041% |
| BeiGene, Ltd. | 2.23 Billion USD | 97.511% |
| Kiromic BioPharma, Inc. | 21.28 Million USD | -161.136% |
| Revolution Medicines, Inc. Warrant | 262.39 Million USD | 78.813% |
| Protagonist Therapeutics, Inc. | 21.27 Million USD | -161.33% |
| Erasca, Inc. | 78.61 Million USD | 29.278% |
| bluebird bio, Inc. | 424.62 Million USD | 86.907% |
| Protagenic Therapeutics, Inc. | 655.25 Thousand USD | -8384.567% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | 97.059% |
| DBV Technologies S.A. | 42.8 Million USD | -29.896% |
| Protagenic Therapeutics, Inc. | 655.25 Thousand USD | -8384.567% |
| Moderna, Inc. | 4.57 Billion USD | 98.784% |
| Vincerx Pharma, Inc. | 6.99 Million USD | -694.786% |
| Fresh Tracks Therapeutics, Inc. | 1.65 Million USD | -3257.204% |
| Molecular Templates, Inc. | 31.17 Million USD | -78.356% |
| Acrivon Therapeutics, Inc. Common Stock | 17.07 Million USD | -225.69% |
| Travere Therapeutics, Inc. | 588.1 Million USD | 90.547% |
| Monte Rosa Therapeutics, Inc. | 124.5 Million USD | 55.347% |
| Spruce Biosciences, Inc. | 27.43 Million USD | -102.629% |
| Celldex Therapeutics, Inc. | 36.45 Million USD | -52.5% |
| Cogent Biosciences, Inc. | 55.63 Million USD | 0.071% |
| MacroGenics, Inc. | 154.2 Million USD | 63.948% |
| RenovoRx, Inc. | 4.46 Million USD | -1144.857% |
| Adicet Bio, Inc. | 37.12 Million USD | -49.772% |
| Prime Medicine, Inc. | 60.78 Million USD | 8.53% |
| Aditxt, Inc. | 28.53 Million USD | -94.855% |
| Adagene Inc. | 45.16 Million USD | -23.082% |
| Estrella Immunopharma, Inc. | 180.7 Thousand USD | -30666.456% |
| Quantum-Si incorporated | 26.63 Million USD | -108.762% |
| Maravai LifeSciences Holdings, Inc. | 697.56 Million USD | 92.03% |
| Acurx Pharmaceuticals, Inc. | 3.04 Million USD | -1727.327% |
| Voyager Therapeutics, Inc. | 114.96 Million USD | 51.64% |
| SciSparc Ltd. | 1.59 Million USD | -3385.598% |
| Vericel Corporation | 127.7 Million USD | 56.466% |
| Revelation Biosciences, Inc. | 5.56 Million USD | -899.036% |
| Minerva Neurosciences, Inc. | 85.35 Million USD | 34.868% |
| Generation Bio Co. | 171.63 Million USD | 67.607% |
| Astria Therapeutics, Inc. | 11.55 Million USD | -381.345% |
| Black Diamond Therapeutics, Inc. | 41.83 Million USD | -32.905% |
| Arcutis Biotherapeutics, Inc. | 252.69 Million USD | 77.999% |
| Invivyd, Inc. | 51.71 Million USD | -7.507% |
| Relay Therapeutics, Inc. | 91.97 Million USD | 39.555% |
| Quoin Pharmaceuticals, Ltd. | 6.5 Million USD | -754.622% |
| Spero Therapeutics, Inc. | 75.49 Million USD | 26.36% |
| Artelo Biosciences, Inc. | 1.02 Million USD | -5345.181% |
| 2seventy bio, Inc. | 310.12 Million USD | 82.073% |
| ADMA Biologics, Inc. | 193.97 Million USD | 71.339% |
| Clene Inc. | 38.95 Million USD | -42.731% |
| Capricor Therapeutics, Inc. | 36.13 Million USD | -53.864% |
| Boundless Bio, Inc. Common Stock | 256.97 Million USD | 78.366% |
| GeoVax Labs, Inc. | 3.51 Million USD | -1479.465% |
| Recursion Pharmaceuticals, Inc. | 190.26 Million USD | 70.78% |
| Citius Pharmaceuticals, Inc. | 12.17 Million USD | -356.46% |
| Contineum Therapeutics, Inc. Class A Common Stock | 198.32 Million USD | 71.967% |
| Relmada Therapeutics, Inc. | 12.19 Million USD | -355.893% |
| Finch Therapeutics Group, Inc. | 48.11 Million USD | -15.556% |
| ALX Oncology Holdings Inc. | 52.84 Million USD | -5.212% |
| Vir Biotechnology, Inc. | 369.85 Million USD | 84.968% |
| Evaxion Biotech A/S | 17.61 Million USD | -215.569% |
| Ocular Therapeutix, Inc. | 160.92 Million USD | 65.454% |
| Verve Therapeutics, Inc. | 153.18 Million USD | 63.707% |
| Trevena, Inc. | 48.26 Million USD | -15.195% |
| Surrozen, Inc. | 8.14 Million USD | -582.57% |
| Tyra Biosciences, Inc. | 21.59 Million USD | -157.445% |
| Cingulate Inc. | 10.36 Million USD | -436.589% |
| Galmed Pharmaceuticals Ltd. | 2.75 Million USD | -1921.647% |
| Unity Biotechnology, Inc. | 37.29 Million USD | -49.081% |
| Tenax Therapeutics, Inc. | 3.58 Million USD | -1450.118% |
| Terns Pharmaceuticals, Inc. | 13.15 Million USD | -322.778% |
| ACADIA Pharmaceuticals Inc. | 317.2 Million USD | 82.473% |
| Connect Biopharma Holdings Limited | 24.84 Million USD | -123.733% |
| Clearmind Medicine Inc. | 3.61 Million USD | -1440.032% |
| Kronos Bio, Inc. | 54.2 Million USD | -2.572% |
| Bolt Biotherapeutics, Inc. | 47.04 Million USD | -18.18% |
| CERo Therapeutics Holdings, Inc. | 22.75 Million USD | -144.27% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -176.993% |
| Statera Biopharma, Inc. | 22.67 Million USD | -145.168% |
| ImmunityBio, Inc. | 1.09 Billion USD | 94.901% |
| Korro Bio, Inc. | 51.75 Million USD | -7.426% |
| Kineta, Inc. | 7.22 Million USD | -669.805% |
| BioVie Inc. | 9.7 Million USD | -473.022% |
| Codexis, Inc. | 49.94 Million USD | -11.311% |
| Celularity Inc. | 102.92 Million USD | 45.987% |
| Crinetics Pharmaceuticals, Inc. | 96.24 Million USD | 42.237% |
| Celcuity Inc. | 51.45 Million USD | -8.057% |
| Virax Biolabs Group Limited | 345.19 Thousand USD | -16005.522% |
| Cibus, Inc. | 206.11 Million USD | 73.027% |
| Eledon Pharmaceuticals, Inc. | 42.47 Million USD | -30.889% |
| eFFECTOR Therapeutics, Inc. | 26.33 Million USD | -111.076% |
| IN8bio, Inc. | 8.77 Million USD | -533.781% |
| Kodiak Sciences Inc. | 213.59 Million USD | 73.971% |
| Annexon, Inc. | 47.11 Million USD | -17.992% |
| Adverum Biotechnologies, Inc. | 89.54 Million USD | 37.911% |
| Assembly Biosciences, Inc. | 96.37 Million USD | 42.312% |
| Avalo Therapeutics, Inc. | 13.68 Million USD | -306.131% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | 97.865% |
| Eyenovia, Inc. | 19.78 Million USD | -181.064% |
| Puma Biotechnology, Inc. | 177.08 Million USD | 68.605% |
| Conduit Pharmaceuticals Inc. | 7.68 Million USD | -623.803% |
| Xilio Therapeutics, Inc. | 24.09 Million USD | -130.695% |
| Arcellx, Inc. | 339.75 Million USD | 83.637% |
| Cardiff Oncology, Inc. | 11.89 Million USD | -367.266% |
| Enanta Pharmaceuticals, Inc. | 245.54 Million USD | 77.358% |
| Regulus Therapeutics Inc. | 9.56 Million USD | -481.358% |
| Moolec Science SA | 13.94 Million USD | -298.665% |
| Acumen Pharmaceuticals, Inc. | 43.15 Million USD | -28.836% |
| Geron Corporation | 146.12 Million USD | 61.954% |
| LAVA Therapeutics N.V. | 50.53 Million USD | -10.02% |
| Royalty Pharma plc | 6.29 Billion USD | 99.117% |
| Atea Pharmaceuticals, Inc. | 39.77 Million USD | -39.771% |
| Greenwich LifeSciences, Inc. | 294.4 Thousand USD | -18783.886% |
| TFF Pharmaceuticals, Inc. | 2.46 Million USD | -2159.712% |
| Mersana Therapeutics, Inc. | 189.15 Million USD | 70.609% |
| Humacyte, Inc. | 114.67 Million USD | 51.52% |
| Structure Therapeutics Inc. | 29.05 Million USD | -91.371% |
| 89bio, Inc. | 59.96 Million USD | 7.284% |
| PMV Pharmaceuticals, Inc. | 26.46 Million USD | -110.087% |
| Avenue Therapeutics, Inc. | 1.19 Million USD | -4548.436% |
| Genelux Corporation | 8.42 Million USD | -560.277% |
| Trevi Therapeutics, Inc. | 6.85 Million USD | -710.9% |
| Lexicon Pharmaceuticals, Inc. | 136.31 Million USD | 59.217% |
| Notable Labs, Ltd. | 4.42 Million USD | -1155.823% |
| Liquidia Corporation | 73.13 Million USD | 23.986% |
| Mustang Bio, Inc. | 17.61 Million USD | -215.542% |
| Immunovant, Inc. | 48.95 Million USD | -13.564% |
| Quantum-Si incorporated | 26.63 Million USD | -108.762% |
| Arbutus Biopharma Corporation | 38.38 Million USD | -44.844% |
| DiaMedica Therapeutics Inc. | 3.1 Million USD | -1691.663% |
| Vera Therapeutics, Inc. | 73.86 Million USD | 24.73% |
| Acasti Pharma Inc. | 11.55 Million USD | -381.053% |
| MiNK Therapeutics, Inc. | 22.6 Million USD | -145.913% |
| Pasithea Therapeutics Corp. | 2.71 Million USD | -1945.143% |
| Xenon Pharmaceuticals Inc. | 36.87 Million USD | -50.759% |
| Elevai Labs, Inc. Common Stock | 1.36 Million USD | -3979.365% |
| NeuroBo Pharmaceuticals, Inc. | 6.09 Million USD | -811.996% |
| Tempest Therapeutics, Inc. | 24.83 Million USD | -123.859% |
| Soleno Therapeutics, Inc. | 23.18 Million USD | -139.8% |
| PepGen Inc. | 34.63 Million USD | -60.536% |
| Moleculin Biotech, Inc. | 12.14 Million USD | -357.801% |
| United Therapeutics Corporation | 1.18 Billion USD | 95.297% |
| Nuvectis Pharma, Inc. | 6.98 Million USD | -696.038% |
| Solid Biosciences Inc. | 38.45 Million USD | -44.561% |
| BriaCell Therapeutics Corp. | 8.55 Million USD | -549.691% |
| Immuneering Corporation | 12 Million USD | -362.972% |
| Lixte Biotechnology Holdings, Inc. | 313.85 Thousand USD | -17613.518% |
| Silo Pharma, Inc. | 1.56 Million USD | -3442.749% |
| Belite Bio, Inc | 4.21 Million USD | -1220.24% |
| XOMA Corporation | 145.58 Million USD | 61.811% |
| ARS Pharmaceuticals, Inc. | 2.42 Million USD | -2189.757% |
| Bionomics Limited | 10.15 Million USD | -447.267% |
| Apogee Therapeutics, Inc. | 21.49 Million USD | -158.691% |
| Alpha Tau Medical Ltd. | 22.91 Million USD | -142.636% |
| uniQure N.V. | 624.01 Million USD | 91.091% |
| Cassava Sciences, Inc. | 14.19 Million USD | -291.654% |
| Estrella Immunopharma, Inc. | 180.7 Thousand USD | -30666.456% |
| Poseida Therapeutics, Inc. | 170.18 Million USD | 67.332% |
| Forte Biosciences, Inc. | 3.66 Million USD | -1416.511% |
| Anebulo Pharmaceuticals, Inc. | 260.58 Thousand USD | -21234.966% |
| Enlivex Therapeutics Ltd. | 6.74 Million USD | -724.0% |
| Conduit Pharmaceuticals Inc. | 7.68 Million USD | -623.803% |
| SeaStar Medical Holding Corporation | 17.38 Million USD | -219.826% |
| FibroBiologics, Inc. Common Stock | 10.56 Million USD | -426.072% |
| Altimmune, Inc. | 16.54 Million USD | -236.106% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | 91.0% |
| Alpha Tau Medical Ltd. | 22.91 Million USD | -142.636% |
| Compugen Ltd. | 55.77 Million USD | 0.322% |
| Peak Bio, Inc. | 20.75 Million USD | -167.886% |
| Zevra Therapeutics, Inc. | 110.46 Million USD | 49.671% |
| Benitec Biopharma Inc. | 4.96 Million USD | -1020.421% |
| Spyre Therapeutics, Inc. | 157.84 Million USD | 64.778% |
| NKGen Biotech, Inc. Common Stock | 75.17 Million USD | 26.045% |
| Zura Bio Limited | 21.29 Million USD | -161.109% |
| PolyPid Ltd. | 17.46 Million USD | -218.269% |
| Aileron Therapeutics, Inc. | 112.39 Million USD | 50.538% |
| NKGen Biotech, Inc. Warrants | 75.17 Million USD | 26.045% |
| Instil Bio, Inc. | 99.8 Million USD | 44.294% |
| argenx SE | 444.95 Million USD | 87.505% |
| Immunome, Inc. | 28.65 Million USD | -93.996% |
| Compass Therapeutics, Inc. | 8.33 Million USD | -566.85% |
| Verona Pharma plc | 58.84 Million USD | 5.516% |
| enGene Holdings Inc. Warrants | 14.47 Million USD | -284.131% |
| Shattuck Labs, Inc. | 14.85 Million USD | -274.152% |
| CervoMed Inc. | 2.59 Million USD | -2041.784% |
| LENZ Therapeutics, Inc. | 4.87 Million USD | -1040.65% |
| Plus Therapeutics, Inc. | 12.73 Million USD | -336.521% |
| Dianthus Therapeutics, Inc. | 10.53 Million USD | -427.72% |
| Moolec Science SA | 13.94 Million USD | -298.665% |
| Enveric Biosciences, Inc. | 2.34 Million USD | -2272.315% |
| AnaptysBio, Inc. | 364.28 Million USD | 84.739% |
| Design Therapeutics, Inc. | 11.95 Million USD | -364.999% |
| Leap Therapeutics, Inc. | 12.68 Million USD | -338.31% |
| NeurAxis, Inc. | 1.91 Million USD | -2806.58% |
| Seelos Therapeutics, Inc. | 38.92 Million USD | -42.816% |
| Lumos Pharma, Inc. | 13.33 Million USD | -316.975% |
| Achilles Therapeutics plc | 19.08 Million USD | -191.273% |
| enGene Holdings Inc. Common Stock | 14.47 Million USD | -284.131% |
| 180 Life Sciences Corp. | 5.38 Million USD | -931.987% |
| Opiant Pharmaceuticals, Inc. | 23.58 Million USD | -135.693% |
| CERo Therapeutics Holdings, Inc. | 22.75 Million USD | -144.27% |
| Nutriband Inc. | 1.07 Million USD | -5052.87% |
| ORIC Pharmaceuticals, Inc. | 30.59 Million USD | -81.696% |
| CG Oncology, Inc. Common stock | 14.51 Million USD | -283.125% |
| Fractyl Health, Inc. Common Stock | 401.27 Million USD | 86.145% |
| Rani Therapeutics Holdings, Inc. | 32.47 Million USD | -71.205% |
| MoonLake Immunotherapeutics | 13.04 Million USD | -326.047% |
| Palisade Bio, Inc. | 2.73 Million USD | -1929.766% |
| Tourmaline Bio, Inc. | 5.25 Million USD | -958.353% |
| Beam Therapeutics Inc. | 478.38 Million USD | 88.379% |
| Neurogene Inc. | 36.54 Million USD | -52.112% |
| Mirum Pharmaceuticals, Inc. | 397.95 Million USD | 86.03% |
| AEON Biopharma, Inc. | 159.88 Million USD | 65.229% |
| CARGO Therapeutics, Inc. Common Stock | 47.65 Million USD | -16.674% |
| Sesen Bio, Inc. | 30.98 Million USD | -79.432% |
| Enliven Therapeutics, Inc. | 25.96 Million USD | -114.149% |
| Kiora Pharmaceuticals, Inc. | 7.6 Million USD | -631.304% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | 71.597% |
| Taysha Gene Therapies, Inc. | 192.05 Million USD | 71.053% |
| Athira Pharma, Inc. | 30.05 Million USD | -84.966% |
| Vaccinex, Inc. | 5.94 Million USD | -835.633% |
| HCW Biologics Inc. | 15.05 Million USD | -269.356% |
| XOMA Corporation | 145.58 Million USD | 61.811% |
| Nektar Therapeutics | 267.04 Million USD | 79.181% |
| Arvinas, Inc. | 644.6 Million USD | 91.375% |
| Tevogen Bio Holdings Inc. | 17.73 Million USD | -213.511% |
| Merus N.V. | 102.15 Million USD | 45.575% |
| Omega Therapeutics, Inc. | 146.35 Million USD | 62.012% |
| Quince Therapeutics, Inc. | 95.12 Million USD | 41.552% |
| Rezolute, Inc. | 11.73 Million USD | -373.797% |
| Clene Inc. | 38.95 Million USD | -42.731% |
| Indaptus Therapeutics, Inc. | 2.84 Million USD | -1852.507% |
| BeyondSpring Inc. | 48.26 Million USD | -15.178% |
| Synlogic, Inc. | 32.89 Million USD | -69.008% |
| Allarity Therapeutics, Inc. | 14.61 Million USD | -280.451% |
| Phio Pharmaceuticals Corp. | 1.63 Million USD | -3302.405% |
| Peak Bio, Inc. | 20.75 Million USD | -167.886% |
| Werewolf Therapeutics, Inc. | 63.45 Million USD | 12.392% |
| Krystal Biotech, Inc. | 39.71 Million USD | -39.989% |
| Karyopharm Therapeutics Inc. | 376.64 Million USD | 85.239% |
| SpringWorks Therapeutics, Inc. | 99.56 Million USD | 44.164% |
| Lipella Pharmaceuticals Inc. | 432.72 Thousand USD | -12747.69% |
| MannKind Corporation | 721.36 Million USD | 92.293% |
| Ikena Oncology, Inc. | 22.33 Million USD | -148.916% |
| Cyclerion Therapeutics, Inc. | 2.08 Million USD | -2565.163% |
| Gyre Therapeutics, Inc. | 102.59 Million USD | 45.808% |
| Gossamer Bio, Inc. | 249.14 Million USD | 77.686% |
| CohBar, Inc. | 1.03 Million USD | -5278.604% |
| Cognition Therapeutics, Inc. | 10.68 Million USD | -420.117% |
| NRx Pharmaceuticals, Inc. | 19.04 Million USD | -191.869% |
| Legend Biotech Corporation | 589.93 Million USD | 90.576% |
| Mural Oncology plc | 37.92 Million USD | -46.581% |
| Biora Therapeutics, Inc. | 132.63 Million USD | 58.084% |
| PaxMedica, Inc. Common Stock | 2.29 Million USD | -2322.103% |
| Disc Medicine, Inc. | 22.87 Million USD | -143.04% |
| Champions Oncology, Inc. | 28.03 Million USD | -98.307% |
| REGENXBIO Inc. | 262.22 Million USD | 78.799% |
| Ensysce Biosciences, Inc. | 3.35 Million USD | -1554.941% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -343.556% |
| Cellectar Biosciences, Inc. | 13.43 Million USD | -313.913% |
| Edgewise Therapeutics, Inc. | 21.2 Million USD | -162.18% |
| Vaxart, Inc. | 34.02 Million USD | -63.395% |
| PharmaCyte Biotech, Inc. | 20.38 Million USD | -172.669% |
| Aldeyra Therapeutics, Inc. | 28.53 Million USD | -94.853% |
| Cellectis S.A. | 249.57 Million USD | 77.724% |
| Longeveron Inc. | 5.33 Million USD | -941.696% |
| Repare Therapeutics Inc. | 41.81 Million USD | -32.943% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | 97.689% |
| Inozyme Pharma, Inc. | 60.36 Million USD | 7.906% |
| Revolution Medicines, Inc. | 262.39 Million USD | 78.813% |
| Nymox Pharmaceutical Corporation | 2.1 Million USD | -2538.6% |
| Third Harmonic Bio, Inc. | 8.62 Million USD | -544.508% |
| ArriVent BioPharma, Inc. Common Stock | 11.8 Million USD | -371.107% |
| AN2 Therapeutics, Inc. | 14.04 Million USD | -295.893% |
| Anixa Biosciences, Inc. | 2.15 Million USD | -2484.625% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 98.92% |
| Denali Therapeutics Inc. | 122.96 Million USD | 54.787% |
| Revelation Biosciences, Inc. | 5.56 Million USD | -899.036% |
| Veru Inc. | 32.81 Million USD | -69.432% |
| Corvus Pharmaceuticals, Inc. | 6.86 Million USD | -709.365% |
| Cingulate Inc. | 10.36 Million USD | -436.589% |
| Passage Bio, Inc. | 39.26 Million USD | -41.601% |
| Context Therapeutics Inc. | 4.19 Million USD | -1226.314% |
| Exicure, Inc. | 8.54 Million USD | -550.313% |
| Day One Biopharmaceuticals, Inc. | 29.5 Million USD | -88.408% |
| Oramed Pharmaceuticals Inc. | 10.48 Million USD | -430.186% |
| Scinai Immunotherapeutics Ltd. | 22.04 Million USD | -152.236% |
| Rhythm Pharmaceuticals, Inc. | 162.98 Million USD | 65.89% |
| Nuvalent, Inc. | 31.82 Million USD | -74.702% |
| ABVC BioPharma, Inc. | 6.36 Million USD | -773.916% |
| Carisma Therapeutics, Inc. | 63.02 Million USD | 11.784% |
| Unicycive Therapeutics, Inc. | 18 Million USD | -208.863% |
| OmniAb, Inc. | 87.4 Million USD | 36.39% |
| Anew Medical, Inc. | 8.24 Million USD | -574.553% |
| Fennec Pharmaceuticals Inc. | 38.28 Million USD | -45.199% |
| Lipocine Inc. | 2.63 Million USD | -2012.581% |
| Lexeo Therapeutics, Inc. Common Stock | 26.27 Million USD | -111.614% |
| Nautilus Biotechnology, Inc. | 40.21 Million USD | -38.255% |
| SAB Biotherapeutics, Inc. | 26.64 Million USD | -108.677% |
| G1 Therapeutics, Inc. | 86.15 Million USD | 35.47% |
| Bellerophon Therapeutics, Inc. | 5.4 Million USD | -929.352% |
| Sage Therapeutics, Inc. | 82.74 Million USD | 32.813% |
| Ocugen, Inc. | 23.98 Million USD | -131.811% |
| Mind Medicine (MindMed) Inc. | 46.4 Million USD | -19.799% |
| Q32 Bio Inc. | 233.12 Million USD | 76.152% |
| Brainstorm Cell Therapeutics Inc. | 9.06 Million USD | -513.228% |
| Alumis Inc. Common Stock | 53.5 Million USD | -3.913% |
| Equillium, Inc. | 27.95 Million USD | -98.86% |
| Kyverna Therapeutics, Inc. | 206.59 Million USD | 73.089% |
| Coya Therapeutics, Inc. | 5.62 Million USD | -888.068% |
| CNS Pharmaceuticals, Inc. | 6.13 Million USD | -806.499% |
| Galera Therapeutics, Inc. | 157.32 Million USD | 64.662% |
| Evelo Biosciences, Inc. | 69.43 Million USD | 19.93% |
| Comera Life Sciences Holdings, Inc. | 9.97 Million USD | -457.391% |
| Dominari Holdings Inc. | 4.63 Million USD | -1099.467% |
| Edesa Biotech, Inc. | 1.84 Million USD | -2918.798% |
| vTv Therapeutics Inc. | 29.56 Million USD | -88.032% |
| Bio-Techne Corporation | 744.34 Million USD | 92.531% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | 55.911% |
| Harmony Biosciences Holdings, Inc. | 344.45 Million USD | 83.86% |
| Prelude Therapeutics Incorporated | 40.57 Million USD | -37.019% |
| Candel Therapeutics, Inc. | 28.95 Million USD | -91.993% |
| iTeos Therapeutics, Inc. | 92.36 Million USD | 39.806% |
| Nkarta, Inc. | 105.6 Million USD | 47.353% |
| BioCardia, Inc. | 4.59 Million USD | -1111.226% |
| Iterum Therapeutics plc | 32.66 Million USD | -70.214% |